Scale -

  • PBT is 0.3 Rs Cr; Continuous Growth over 3 years
  • Quarterly Profit is 0.23 Rs Cr; Continuous Growth over 3 Quarters
  • Revenue is 14.66 Rs Cr; Continuous Decline over 3 years; in Bottom Quartile
  • Ebitda is 1.24 Rs Cr; in Bottom Quartile
  • Quarterly Revenue is 3.15 Rs Cr; in Bottom Quartile
  • Quarterly Ebitda is 0.32 Rs Cr; in Bottom Quartile

Profitability -

  • Quarterly Profit margin is 7 %; Continuous Growth over 3 Quarters

Return -

  • Asset Turnover is 101 %; Continuous Decline over 3 years

Efficiency -

  • Current Ratio is 9.65; Annual Growth is 248 %; in Top Quartile; 5 Year CAGR is 26 %
  • Quick Ratio is 8.72; Annual Growth is 347 %; in Top Quartile; 5 Year CAGR is 26 %
  • Operating cash flow is 3.92 Rs Cr; Annual Growth is 208 %

Solvancy -

  • Debt/Equity is 0.01; Annual Decline is -97 %; in Bottom Quartile
  • Long term Debt is 0.03 Rs Cr; Annual Decline is -67 %
  • Total Debt is 0.08 Rs Cr; Annual Decline is -98 %; in Bottom Quartile

Quality -

  • Operating cashflow/ebitda is 316 %; Annual Growth is 216 %; in Top Quartile
  • Operating cashflow/PAT is 5.03 %; Annual Growth is 220 %; in Top Quartile
  • Change in Inventories/Total Expenses is -2 %; Annual Decline is -209 %
  • Current Tax/PAT is 38 %; Continuous Growth over 3 years; in Top Quartile
  • Other Expenses/Total Expenses is 13 %; Continuous Growth over 3 years
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Abha Agrawal gets fresh trem as Ishita Drugs NE Director
Read More
  • Past/current